patent cliff

Biotech dealmaking has reached a "torrid pace" in 2026, with more transactions exceeding $1 billion already completed this year than in all of 2025 combined, according to Krishna Veeraraghavan, global co-head of M&A at Paul Weiss, who discussed the trend…